CU Programme of Idarucizumab for Japanese Patients

Inclusion criteria: * Currently taking dabigatran etexilate. * Age \>= 20 years at entry. * Written Informed consent * Group A: \-- Uncontrolled or life-threatening judged by the physician to require a reversal agent. * Group B: * A condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours. Exclusion criteria: * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol). * Group A: * Patients with minor bleeding (e.g. epistaxis, hematuria) who can be managed with standard supportive care. * Patients with no clinical signs of bleeding. * Group B: * surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.